mediaire

mediaire operates in medical imaging software, with a focused offering of AI-assisted MRI analysis for radiology workflows rather than a broad general-purpose healthcare platform. Its products address several distinct imaging tasks: mdbrain supports brain MRI evaluation, including volumetry, lesion characterization, aneurysm detection and tumor differentiation; mdprostate analyzes prostate MRI and classifies lesions using PI-RADS 2.1; and mdknee is described as a prototype for cartilage-damage classification. The company’s stated approach combines medical and technical expertise and develops its tools in cooperation with the radiology community, pointing to workflow fit and specialty-specific analysis as differentiators. The company has raised $15,109,987 in total, including a $12 million round led by LBO France in November 2024. Its competitive position is therefore best characterized by its focused MRI use cases and radiology-oriented product suite, not by an unverified ranking against specific companies.

mediaire’s disclosed financing history shows an early Seed round in April 2019, a further €2 million Seed round in December 2020, and a €12 million investment announced in November 2024. Across the rounds, High-Tech Gründerfonds (HTGF) appears as an early backer, with primeCROWD and LIFTT participating in the 2020 financing and LBO France leading the 2024 round. Product development has also broadened across brain and prostate MRI, with mdbrain and mdprostate described as analysis tools and mdknee remaining a prototype. The company is listed in the 51–100 employee range, while current hiring signals include technical support, key-account management, marketing and working-student roles. Those openings suggest investment in customer-facing and commercial functions alongside technical work, but they do not establish net headcount growth.